Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Acetazolamide and N-acetylcysteine in the treatment of chronic mountain sickness (Monge's disease).

Sharma S, Gralla J, Ordonez JG, Hurtado ME, Swenson ER, Schoene RB, Kelly JP, Callacondo D, Rivard C, Roncal-Jimenez C, Sirota J, Fuquay R, Jackson BP, Swenson KE, Johnson RJ, Hurtado A, Escudero E.

Respir Physiol Neurobiol. 2017 Dec;246:1-8. doi: 10.1016/j.resp.2017.07.005. Epub 2017 Jul 15.

PMID:
28720395
2.

Acetazolamide for Monge's disease: efficiency and tolerance of 6-month treatment.

Richalet JP, Rivera-Ch M, Maignan M, Privat C, Pham I, Macarlupu JL, Petitjean O, León-Velarde F.

Am J Respir Crit Care Med. 2008 Jun 15;177(12):1370-6. doi: 10.1164/rccm.200802-196OC. Epub 2008 Apr 3.

PMID:
18388356
3.

Acetazolamide: a treatment for chronic mountain sickness.

Richalet JP, Rivera M, Bouchet P, Chirinos E, Onnen I, Petitjean O, Bienvenu A, Lasne F, Moutereau S, León-Velarde F.

Am J Respir Crit Care Med. 2005 Dec 1;172(11):1427-33. Epub 2005 Aug 26.

PMID:
16126936
4.

Excessive erythrocytosis, chronic mountain sickness, and serum cobalt levels.

Jefferson JA, Escudero E, Hurtado ME, Pando J, Tapia R, Swenson ER, Prchal J, Schreiner GF, Schoene RB, Hurtado A, Johnson RJ.

Lancet. 2002 Feb 2;359(9304):407-8.

PMID:
11844517
5.

Effect of acetazolamide on ventilatory response in subjects with chronic mountain sickness.

Rivera-Ch M, Huicho L, Bouchet P, Richalet JP, León-Velarde F.

Respir Physiol Neurobiol. 2008 Aug 31;162(3):184-9. doi: 10.1016/j.resp.2008.06.010. Epub 2008 Jun 17.

PMID:
18603026
6.

Plasma soluble erythropoietin receptor is decreased during sleep in Andean highlanders with Chronic Mountain Sickness.

Villafuerte FC, Corante N, Anza-Ramírez C, Figueroa-Mujíca R, Vizcardo-Galindo G, Mercado A, Macarlupú JL, León-Velarde F.

J Appl Physiol (1985). 2016 Jul 1;121(1):53-8. doi: 10.1152/japplphysiol.00107.2016. Epub 2016 Apr 28.

7.

Acute Mountain Sickness Symptom Severity at the South Pole: The Influence of Self-Selected Prophylaxis with Acetazolamide.

Harrison MF, Anderson PJ, Johnson JB, Richert M, Miller AD, Johnson BD.

PLoS One. 2016 Feb 5;11(2):e0148206. doi: 10.1371/journal.pone.0148206. eCollection 2016.

8.

Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange.

Grissom CK, Roach RC, Sarnquist FH, Hackett PH.

Ann Intern Med. 1992 Mar 15;116(6):461-5.

PMID:
1739236
10.

Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: a randomized, placebo-controlled trial.

Chow T, Browne V, Heileson HL, Wallace D, Anholm J, Green SM.

Arch Intern Med. 2005 Feb 14;165(3):296-301.

PMID:
15710792
11.

Altitude Sickness Prevention with Ibuprofen Relative to Acetazolamide.

Burns P, Lipman GS, Warner K, Jurkiewicz C, Phillips C, Sanders L, Soto M, Hackett P.

Am J Med. 2019 Feb;132(2):247-251. doi: 10.1016/j.amjmed.2018.10.021. Epub 2018 Nov 10.

PMID:
30419226
12.

Exercise limitation of acetazolamide at altitude (3459 m).

Bradwell AR, Myers SD, Beazley M, Ashdown K, Harris NG, Bradwell SB, Goodhart J, Imray CH, Wimalasena Y, Edsell ME, Pattinson KT, Wright AD, Harris SJ; Birmingham Medical Research Expeditionary Society.

Wilderness Environ Med. 2014 Sep;25(3):272-7. doi: 10.1016/j.wem.2014.04.003. Epub 2014 Jun 13.

PMID:
24931587
13.

Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: a prospective, double-blind, randomized, placebo-controlled trial.

Basnyat B, Gertsch JH, Johnson EW, Castro-Marin F, Inoue Y, Yeh C.

High Alt Med Biol. 2003 Spring;4(1):45-52.

PMID:
12713711
14.

Treatment of chronic mountain sickness: critical reappraisal of an old problem.

Rivera-Ch M, León-Velarde F, Huicho L.

Respir Physiol Neurobiol. 2007 Sep 30;158(2-3):251-65. Epub 2007 May 10. Review.

PMID:
17580125
15.

Budesonide Versus Acetazolamide for Prevention of Acute Mountain Sickness.

Lipman GS, Pomeranz D, Burns P, Phillips C, Cheffers M, Evans K, Jurkiewicz C, Juul N, Hackett P.

Am J Med. 2018 Feb;131(2):200.e9-200.e16. doi: 10.1016/j.amjmed.2017.05.034. Epub 2017 Jun 28.

PMID:
28668540
16.

Medroxyprogesterone at high altitude. The effects on blood gases, cerebral regional oxygenation, and acute mountain sickness.

Wright AD, Beazley MF, Bradwell AR, Chesner IM, Clayton RN, Forster PJ, Hillenbrand P, Imray CH; Birmingham Medical Research Expeditionary Society.

Wilderness Environ Med. 2004 Spring;15(1):25-31.

PMID:
15040503
17.

Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness.

van Patot MC, Leadbetter G 3rd, Keyes LE, Maakestad KM, Olson S, Hackett PH.

High Alt Med Biol. 2008 Winter;9(4):289-93. doi: 10.1089/ham.2008.1029.

PMID:
19115912
18.

Reduced Acetazolamide Dosing in Countering Altitude Illness: A Comparison of 62.5 vs 125 mg (the RADICAL Trial).

McIntosh SE, Hemphill M, McDevitt MC, Gurung TY, Ghale M, Knott JR, Thapa GB, Basnyat B, Dow J, Weber DC, K Grissom C.

Wilderness Environ Med. 2019 Mar;30(1):12-21. doi: 10.1016/j.wem.2018.09.002. Epub 2019 Jan 8.

PMID:
30630671
19.

The role of menopause in the development of chronic mountain sickness.

León-Velarde F, Ramos MA, Hernández JA, De Idiáquez D, Muñoz LS, Gaffo A, Córdova S, Durand D, Monge C.

Am J Physiol. 1997 Jan;272(1 Pt 2):R90-4.

PMID:
9038995
20.

Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial.

Basnyat B, Gertsch JH, Holck PS, Johnson EW, Luks AM, Donham BP, Fleischman RJ, Gowder DW, Hawksworth JS, Jensen BT, Kleiman RJ, Loveridge AH, Lundeen EB, Newman SL, Noboa JA, Miegs DP, O'Beirne KA, Philpot KB, Schultz MN, Valente MC, Wiebers MR, Swenson ER.

High Alt Med Biol. 2006 Spring;7(1):17-27.

PMID:
16544963

Supplemental Content

Support Center